Navigation Links
Studies Show Pterostilbene Shows Promise for Anti-Aging and Maintaining Healthy Brain

Houston, TX (PRWEB) January 09, 2014

With 1 in 3 seniors dying with Alzheimer’s or another dementia (source), scientists have long been fighting to find a way to preserve brain health as we age. Now, hope comes from a little-known compound found in blueberries called pterostilbene. In clinical studies, pterostilbene has shown promise as a treatment in the protection against age-related diseases, including Alzheimer’s disease.
In the September 2012 study published first in Neurobiology of Aging, researchers looked at mice that were genetically developed as a model of age-related cognitive decline. The mice were give two different compounds containing pterostilbene and resveratrol. The study found that pterostilbene was the most effective at positively affecting brain function. Now, researchers see hope that pterostilbene could offer the same brain-boosting benefits in humans.
The researchers said, “While it is yet to be determined whether the cognitive improvements induced by pterostilbene in the SAMP8 model can be applied to humans, recent reports demonstrate that fruits containing pterostilbene such as blueberries ameliorate cognitive function in aged humans.”

With so many positive cognitive enhancement benefits associated with pterostilbene, it’s no wonder many people are searching for ways to add more of this potent compound to their diet. It was even named one of the best nootropics by A new memory enhancement supplement, Biohack Pure, features pterostilbene as a key ingredient.

“Based on all the research we’ve seen, pterostilbene is a highly effective antioxidant that fights free radicals and plays a key role in cognitive enhancement,” said Jonathan Weisman, president at Biohack Nutrition, makers of Biohack Pure. “We’re really excited for the potential of this berry compound at helping preserve brain health and preventing cognitive decline.”
For more information, visit

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. S*BIOs Novel JAK2 Inhibitor Pacritinib (SB1518) and Histone Deacetylase Inhibitor Pracinostat (SB939) Demonstrate Promising Activity in Phase 2 Studies for Patients with Myelofibrosis (MF)
2. Studies Assess Hydroxyurea Therapy and Pre-Operative Transfusions for Patients with Sickle Cell Disease
3. Accelerate Brain Cancer Cure and Exosome Diagnostics Collaborate to Advance Clinical Studies of Exosome Biofluid Molecular Diagnostics Technology in Brain Cancer
4. Lupus Research Institute Awards $3.6 Million for Novel Studies Driving Wide-Ranging New Science in Lupus
5. EMD Millipore Partners with Charles River Laboratories for Improved Viral Clearance Studies
6. Novel compound halts tumor spread, improves brain cancer treatment in animal studies
7. Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain
8. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
9. NIH Awards New England Biolabs a Phase II SBIR Grant for the Research and Development of Novel Enzymes for Epigenetic Studies
10. Genomic Health Announces Presentation of Six Studies at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium
11. RPCI-Led Study: FAK Inhibitor Proves Effective Against Brain Tumors in Preclinical Studies
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... 23, 2016 A person commits a crime, and ... to track the criminal down. An outbreak of ... Drug Administration (FDA) uses DNA evidence to track down the ... Sound far-fetched? It,s not. The FDA has increasingly used a ... of foodborne illnesses. Put as simply as possible, whole genome ...
Breaking Biology Technology:
(Date:5/9/2016)... , UAE, May 9, 2016 ... it comes to expanding freedom for high net worth ... Even in today,s globally connected world, there is still ... system could ever duplicate sealing your deal with a ... second passports by taking advantage of citizenship via investment ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
Breaking Biology News(10 mins):